Precision Biosensor프리시젼바이오

Precision Biosensor remains loss-making, with trailing revenue of ₩23.7B and operating losses continuing into 2026.

The company is a point-of-care diagnostics maker selling immunodiagnostic and clinical chemistry products, partly through its US subsidiary Nano-Ditech. Trailing twelve-month figures to H1 2026 show revenue of ₩23.7B, an operating loss of ₩3.6B and a net loss of ₩6.4B, with borrowings of ₩11.9B against cash of ₩1.5B. The share price is ₩1,474, down 50.8% over the past year, and the market cap is about ₩32.4B.

What stands out

• Revenue has been broadly flat for several years, at about ₩19–20B in each of 2022 to 2025, after a 28.8% jump in 2022.
• Operating margin was -15.3% on a trailing basis to H1 2026, an improvement on the -27% reported for full-year 2025, though still negative.
• Net loss in 2025 was ₩10.0B, and trailing free cash flow is negative at about ₩1.4B.
• Liabilities are 43.8% of equity and borrowings are well above cash, so the balance sheet is a key point of pressure.
• Foreign ownership fell from 0.2% to 0%, and 20-day flows show foreign net selling while retail was a net buyer.
• Recent filings include several notices on acquisitions of convertible bonds, but the data does not explain their terms or size.

What to watch

• The next quarterly or annual report, to see whether the trailing operating margin improvement continues and whether losses narrow.
• Further filings on convertible bonds, which could bear on dilution and financing needs; the data does not say how they affect the share count.
• Debt repayment capacity given borrowings of ₩11.9B against cash of ₩1.5B; no news headlines were available in the data to add context.